Dr. Rahul Baxi highlights that a new Rs 16,000-a-month weight-loss injection isn't a miracle solution without essential ...

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

In the first arrangement of its kind, Eli Lilly to connect patients through telemedicine to providers of Alzheimer’s drugs.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

A U.S. federal judge approves a deal between Novo Nordisk (NVO) and Minnesota that settled a lawsuit over high insulin prices ...

Investing in stocks remains one of the best ways to accumulate capital over long periods. Companies that can last -- and thrive -- that long are rare, but let's consider two brilliant examples ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

With approximately 101 million individuals living with diabetes, increasing access to insulin and advanced treatments is ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...